| Autor: |
Seok Won Jung, Shi Jung Sung, Sung-Jo Bang, Byung Uk Lee, Min-Ho Kim, In Du Jeong, Chang Jae Kim, Neung Hwa Park, Bo Ryung Park, Eun Hye Kim, Jung Woo Shin, Jae Ho Park, Jae Hee Kim, J. H. Park, Byung Gyu Kim |
| Rok vydání: |
2015 |
| Předmět: |
|
| Zdroj: |
Journal of Gastroenterology and Hepatology. 30:1514-1521 |
| ISSN: |
0815-9319 |
| Popis: |
Background and Aim In the past decade, many chronic hepatitis B (CHB) patients have undergone sequential treatment with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) to manage antiviral resistance or insufficient suppression of HBV-DNA. Very limited data are available on the efficacy of tenofovir (TDF) rescue regimens in patients with multidrug resistance (MDR). Methods We investigated the antiviral efficacy of TDF/LAM combination therapy versus TDF/ETV combination therapy in 52 patients who failed three previous antiviral therapies. Results The study subjects were treated with TDF/LAM combination therapy (n = 25) or TDF/ETV combination therapy (n = 27) for more than six months. Virologic response (VR) occurred in 39 (75%) patients (19 patients belonged to the TDF/LAM group and 20 patients belonged to the TDF/ETV group). The VR rates were not different between the TDF/LAM and TDF/ETV groups (56.0% vs 51.9% at month 12, and 72.0% vs 78.8% at month 18; log rank P = 0.515). In addition, treatment efficacy of TDF/LAM combination or TDF/ETV combination was not statistically different according to types of MDR. In multivariate analysis, absolute HBV-DNA level at the start of TDF rescue treatment (P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text